Researchers hope that delivering stem cells directly into the brain will stimulate the body’s own repair mechanisms, potentially encouraging existing neural stem cells to become more active.

The phase one trial involved six patients with Alzheimer’s, who received either 2m or 5m cells. All had evidence of amyloid accumulation, and underwent follow-up assessments over 12 months.

Five of the six showed cognitive improvements 12 weeks after treatment when measured on the Alzheimer’s Disease Assessment Scale, a standard test of memory and thinking.

Brain scans at 12 weeks also suggested a 23.6 per cent reduction in amyloid, while levels of phosphorylated tau, another protein associated with Alzheimer’s, remained reduced at the end of the year.

Researchers also reported improvements in other biological markers associated with nerve cell damage.

Dr Duma suggested that the falloff in the improvement in the following year could reflect the fact that patients had received only one injection.

No adverse events were recorded in the six patients during the trial, but experts warned that the findings remain highly preliminary.

Without a placebo group, it is impossible to determine whether the changes were caused by the treatment, and there is no proof that the injections regenerated brain cells or slowed Alzheimer’s progression.

Dr Duma acknowledged that researchers did not yet understand precisely how the treatment might work.

“We have no idea how it really works,” he told delegates, suggesting that several possible biological mechanisms were being investigated.

‘ It’s an exciting start’

The US Food and Drug Administration has granted the programme fast-track designation, intended to support the development of treatments for serious conditions with unmet medical needs.

A larger phase two trial has received regulatory clearance and will investigate whether repeated treatment produces more sustained benefits.

Patients will receive injections every two months for a year, followed by four months of monitoring. The approach represents a striking departure from the first generation of Alzheimer’s treatments, which work by clearing amyloid plaques from the brain.

Scientists are increasingly exploring whether tackling inflammation, tau tangles and other forms of brain damage could provide additional benefits.

But while stem cell treatment offers the possibility of addressing several disease processes at once, much larger controlled trials will be needed to establish whether it can deliver meaningful improvements for patients.

Dr Katharina Cosker, research programmes manager at Alzheimer’s Research UK, said: “The first human trial of a potential stem cell treatment has delivered very encouraging early findings.

“Not only has it appeared safe in patients, but researchers have also reported some promising changes in Alzheimer’s-related biomarkers. It’s an exciting start, but there’s much more to learn.

“The move towards Phase 2 is an important milestone. The next step is to establish whether these early findings translate into meaningful and sustained benefits for patients.

“Not long ago, changing the course of Alzheimer’s seemed impossible. Now, more than 150 experimental treatments are being tested in more than 190 trials worldwide. The pace of progress is accelerating and, with every new discovery, we move closer to a future where a cure could become a reality.”